NovaTears topical treatment for dry eye disease and meibomian gland dysfunction is now available in Australia, Novaliq announced in a press release.
AFT Pharmaceuticals, a New Zealand-based pharmaceutical company, is commercializing the product throughout Australia and New Zealand, where it was launched 8 months ago, the release said.
“With the introduction of NovaTears, dry eye sufferers in Australia now have a new and highly efficacious treatment option that provides significant improvement to the signs and symptoms of evaporative DED,” Christian Roesky, PhD, managing director and
Uncategorized